Douglas Rubinson

24PUBLICATIONS
214CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursNuclear medicinePredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

|Feb 13, 2026
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun

|Nov 20, 2025
Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors.

Kimberly J Perez, Nora Horick, Joanna Baginksa

|Oct 11, 2025
Causes of Death Among Individuals With Lynch Syndrome in the Immunotherapy Era.

Asaf Maoz, Leah Biller, Marios Giannakis

|Sep 02, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

Rishi Surana, Micaela Morgado, Ashwin Somasundaram

|Jun 12, 2025
Clinical Implications of a Large-Scale Voluntary Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary Results.

Lucy Yu, Jennifer Espiritu, Krishna Patel

Pageof 4

Frequent Collaborators

11 joint publications

Andrew J Aguirre

10 joint publications

Brian M Wolpin

10 joint publications

Kimberly Perez

10 joint publications

Harshabad Singh